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INTRODUCTION 43
Over the past decade, progress against the global tuberculosis (TB) crisis has slowed, with TB 44 becoming the world's leading single infectious disease killer, accounting for 1.6 million deaths in 45 2017. 1 Although TB is preventable and treatable, global efforts to end the epidemic have been off 46 target according to the World Health Organization (WHO)'s annual TB reports over the last 7 years -47 an estimated 42 million people out of nearly 67 million were diagnosed and put on treatment, 48 missing close to 25 million people with TB. 1, 2, 3, 4, 5, 6, 7 In 2017, an estimated 10 million people were 49 infected with TB, but almost 40% of them, and 75% of the 558,000 people with drug-resistant (DR)-50 TB, were missed from diagnosis and treatment. 1 
51
KEY MESSAGES
What is already known?
• Countries may be slow to adopt and implement updated World Health Organization (WHO) Tuberculosis (TB) testing, treatment, and prevention recommendations.
• Implementing updated TB guidelines from WHO is a fundamental first step to honoring international commitments, made through the United Nations (UN) Sustainable Development Goals (SDGs) and UN High-Level Meeting on TB Political Declaration, to end TB by 2030.
What are the new findings?
• Of 29 mostly high TB burden countries, none had fully aligned their national guidelines with WHO recommendations, although some progress has been made since 2015.
• A lack of alignment with WHO recommendations was found across all policy areas surveyed, including prevention, diagnosis, treatment, models of care and drug regulation, particularly regarding uptake of newer, faster, more effective approaches.
What do the new findings imply?
• To reach global TB targets, greater political will is needed to adopt and implement internationally recognized care guidelines more rapidly, and specifically, to keep up with the latest recommendations.
• Periodic surveys of progress at the national level are a valuable way to identify specific areas where countries or regions have fallen behind and that require specific policy and/or programmatic attention.
developed in the past several years and recommended by WHO. These newer tools and strategies 53 range in modality from diagnosis and treatment, to prevention and patient-centered models of care. 54
Through the United Nations (UN) Sustainable Development Goals (SDGs) 8 and UN High-Level 55
Meeting on TB Political Declaration, 9, 10 countries have committed to ending TB by 2030, and a 56 critical first step is to ensure national TB guidelines reflect WHO policy recommendations. However, 57 countries with considerable TB burdens have been slow to adopt and implement WHO 58 recommendations on the use of newer tools and strategies, hindering access for people affected by 59 TB who need them. 60
For the first time in nearly half a century, new tools that substantially improve TB diagnosis and 61 treatment have become available in the past several years. Newer diagnostic tests, such as Xpert 62 MTB/RIF, and two newer drugs for treating DR-TB, bedaquiline (BDQ) and delamanid (DLM), have 63 been recommended by WHO in the last decade. 11 These innovations are desperately needed; using 64 the decades-old standard treatment, the cure rate for multidrug-resistant (MDR)-TB is 55%, 65 dropping to 34% for those with extensively drug-resistant (XDR-)TB. 1 While evidence accumulates 66
showing that BDQ and DLM improve treatment outcomes, these newer drugs remained inaccessible 67 to nearly 90% of people eligible to receive them in 2017, based on WHO recommendations at the 68 time. 12 
69
Improved strategies in TB prevention and models of care are also recommended internationally. For 70 prevention, WHO recommends testing and treatment of latent TB infection in high-risk 71 populations, 13 as well as other strategies such as active case finding. The first pillar of the WHO End 72 TB Strategy is "Integrated, patient-centered TB care and prevention", in which decentralized, 73 community-based models of care are recommended as the preferred treatment strategy.
14 Another 74 important model of care is integrated treatment of TB and HIV for people living with or at risk for 75 either disease. 76 three surveys on the status of key TB policies and related practices in high-burden countries, to 78 monitor progress and identify gaps in the adoption of WHO recommendations into national TB 79 programs. 15, 16, 17 Called the "Out of Step" (OOS) surveys, these reports were comprehensive, with the 80 latest report examining 47 policy indicators in five areas -diagnostics, models of care, treatment, 81 prevention, and drug regulation -across 29 countries. 17 
82
Here we present the findings of a subset of key policy and related practice indicators from the most 83 recent survey and discuss their implications on access to diagnosis and treatment for people with TB. 84
As our survey was conducted before new 2018 WHO DR-TB treatment recommendation updates, we 85 provide here a snapshot of the state of national TB policy adoption and levels of care compared to 86 WHO recommendations at the time of study in late 2016 to early 2017. 87
88
METHODS
89
A detailed description of the methodology can be found in the Supporting Information. 90
Country Inclusion 91
The 2017 OOS survey was conducted in 29 countries between October 2016 and May 2017, which 92 together were home to 82% of the global TB burden (Table 1) . These countries were selected based 93 on having a high burden of TB, MDR-TB, and/or TB/HIV co-infection according to WHO criteria The questionnaire asked whether national policies were aligned with (had adopted) current WHO 117 policies, calling for yes or no answers; in cases of no response or unclear answers, the answer was 118 recorded as "unknown". If yes, then the questionnaire asked if these policies had been implemented 119 or not. An additional box for each question asked the respondents to identify the specific policy 120 document used to support their answer. 121
In this study, we analyzed a subset of 23 Only data that could be verified with no discrepancies were included in this comparison, so for some 148 parameters the denominators were less than 23. 149
RESULTS
150
Diagnosis 151
To ensure people with TB are treated appropriately, and to prevent further transmission, diagnosis 152 needs to be quick and accurate. The WHO End TB Strategy calls for all countries to implement initial 153 diagnostic testing with a WHO-recommended rapid diagnostic test by 2020. microscopy. 20 Our findings showed that Xpert MTB/RIF was adopted in policy as the initial test for all 157 suspected TB cases by only about half (52%, 15/29) of the countries surveyed ( Figure 1 ). This was an 158 improvement on the 2015 OOS survey, when only 32% (7/22) of countries had adopted the use of 159 Xpert MTB/RIF as an initial test in their policies, compared to 68% (15/22) of these same countries in 160 2017 ( Figure 2) . 161 recommended the use of TB lateral flow urine lipoarabinomannan assay (TB-LAM) to assist the 163 diagnosis of TB for co-infected people with CD4 cell counts ≤100 cells/μl plus TB symptoms, or those 164 who are very ill. 21 We found that only two countries had adopted a guideline reflecting this 165 recommendation, but neither had implemented it (Figure 1 ). Three other countries used TB-LAM in 166 selected facilities, while two others used it for research purposes only. 167
The WHO End TB Strategy includes detecting all cases of DR-TB through drug-susceptibility testing 168 
Models of Care 193
WHO recommendations in 2017 stated that community-or home-based treatment is the preferred 194 option for people on TB treatment, and that decentralized models of care are recommended for TB patients, unless they are extremely ill.
14 The healthcare facility level at which TB treatment can be 196 initiated, as well as the requirement of hospitalization for treatment, are two indicators that can be 197 looked at to assess the extent to which countries have implemented decentralized models of care. 198
Decentralized initiation of DS-TB treatment was relatively widespread among the countries 199 surveyed, with some progress since 2015 (Figures 2-3 Another key model of care is integrated TB/HIV treatment. TB is the leading cause of death among 216 people living with HIV/AIDS (PLWHA), and PLWHA are 26-31 times more likely to develop active TB. 22 
13
Since 2015, WHO has recommended antiretroviral therapy (ART) for all PLWHA, 23 called the "Test 218
and Start" approach. Given the benefits of this approach in reducing morbidity and mortality due to 219 TB, implementation of this policy is an urgent step for countries with a high burden of HIV/TB co-220 infection. Our survey found that WHO's "Test and Start" policy had been adopted by only 41% 221 (12/29) of countries, and 11 of these countries had implemented the policy (Figure 3) 24 and 2014, 25 respectively. In January 2018, WHO 234 updated the guidance around the use of DLM, 26 and in August 2018, updated guidance on the use of 235 BDQ for MDR-TB treatment. 27 Our survey was conducted prior to these newer guidelines (see 236 Discussion). 237
At the time of the survey, BDQ was included in the national guidelines for DR-TB treatment in 79% 238 In 2016, the WHO-recommended a shorter treatment regimen for rifampicin resistant (RR)-or MDR-245 TB using existing drugs but reducing the treatment duration from 20 months to 9-12 months. 28 By 246 the time of the survey, adoption and implementation of this regimen had been minimal, but the 247 recommendation was also relatively new at that time. We found that the 9-month MDR-TB 248 treatment regimen was included in the guidelines in only 45% (13/29) of the countries surveyed; and 249 only 9 countries had implemented this recommendation (Figure 4) . 250
The lack of child-friendly drug formulations complicated pediatric TB treatment until December 251 2015, when new fixed-dose combinations (FDCs) of pleasant-tasting, WHO-recommended pediatric 252 drug formulations for DS-TB became available. 29 Despite transforming TB treatment for children, the 253 new pediatric TB FDCs were the standard of care in only 50% (14/28) of countries, and were 254 implemented in only 7 of those countries (Figure 4) . 255 These results illustrate that many countries' TB guidelines were not aligned with WHO 302 recommendations at the time of the survey. While some progress had been made in the last few 303 years, a number of countries' TB guidelines lagged behind in key critical areas. While innovations 304 such as the Xpert MTB/RIF test and newer drugs BDQ and DLM offer new hope for the diagnosis and 305 treatment of TB, a lack of adoption and implementation at national level misses opportunities to 306 reduce TB infections and deaths and hinders progress towards ending TB by 2030. 307
The Xpert MTB/RIF-resistance test, and the next-generation Xpert MTB/RIF Ultra test, are WHO-308 recommended rapid molecular tests that diagnose TB and detect rifampicin resistance in less than 309 two hours. 30 Until Xpert MTB/RIF entered the market in 2010, diagnosing TB relied on traditional 310 sputum smear microscopy, which detected only half of all TB cases and could not diagnose drug 311 resistance. Our findings showed that adoption of the Xpert MTB/RIF test has been slow: seven years 312 after the WHO recommendation on use of Xpert MTB/RIF, just under half of the countries surveyed 313 had yet to adopt it as an initial test for TB. Widespread use of this test has the potential to drastically 314 reduce the TB diagnostic gap, get more people on appropriate treatment, and prevent further 315 transmission. Others have reported significant financial and logistical challenges with the use and 316 scale-up of Xpert MTB/RIF. 31, 32 Countries need to address the specific challenges they face to 317 increase access to this diagnostic tool. 318
Community-based, decentralized models of care enable people with TB to access care close to 319 where they live and are associated with high treatment initiation and reduction in time to 320 treatment; 33 improved treatment outcomes including survival; 34 and cost-effectiveness. 35, 36, 37, 38 321
Compared with hospitalization, studies have found that hospital-based treatment does not result in 322 better outcomes than community-based treatment for DR-TB. 39, 40 MSF experience in South Africa 323
showed DR-TB treatment initiation at the district level resulted in high treatment initiation and 324 reduced time to treatment in patients. 41 With only one in five people with DR-TB completing the 325 21 diagnostic and treatment pathway in 2015, recommending the initiation of TB treatment at the 326 community level presents an opportunity to improve this outlook. 327
In addition, WHO has long recognized the benefits of providing TB care integrated with HIV care, 42 
328
and in 2012 recommended the provision of TB and HIV services at the same location and time, i.e., a 329 "one-stop shop" for diagnosis and treatment. 43 The need to expand collaborative TB/HIV activities is 330 further emphasized in the WHO End TB Strategy and should be prioritized by countries in which TB 331 and HIV are dual public health concerns. 332
The results are in line with pre-existing reports of the slow adoption and implementation of the use 333 of BDQ and DLM, 44 demonstrating that relatively few MDR-TB patients who could benefit from these 334 newer drugs are receiving them. In 2016, just over 4,300 people received BDQ, and only 469 people 335 received DLM outside of clinical trials or compassionate use programs. 45 Despite this, the majority of 336 people with MDR-TB are left to unnecessarily endure treatment with older, more toxic and less 337 effective treatment options. MSF is working with national programs to offer BDQ and/or DLM to 338 people with no other treatment options, and has provided programmatic evidence showing that the 339 combined use of these drugs provides strong signs of effectiveness for patients with few remaining 340 options. 46 Countries can procure both these newer drugs from Stop TB Partnership's Global Drug 341 Facility. 47 Given the poor treatment success rates and high toxicity of existing regimens for MDR-TB, 342 it is critical that countries quickly adopt and widely implement international guidelines on the use of 343 BDQ and DLM. 344
Shorter treatment regimens are also urgently needed. Today, people with TB continue to face long, 345 arduous treatment courses that can last for up to two years and require tens of thousands of pills 346 and injections. At the time of the survey, short-course 9-month regimen was recommended by 347 WHO. MSF showed that patients treated with a 9-month regimen had treatment outcomes similar 348 to current standards of care. 48 Modelling the impact of shorter treatment on MDR-TB incidence 349 22 found that it has the potential to markedly reduce the incidence of MDR-TB if it was to be expanded 350 in the absence of additional drug resistance. 49 Although not part of a specific WHO recommendation, we looked at national drug regulation 352 practices in this study because they have a direct effect on country-level access to TB medicines. We 353 assessed national registrations of BDQ and DLM, as well as the availability of compassionate use 354 programs, accelerated registration, or utilization of the WHO CRP for unregistered drugs. Not 355 presented here, the 2017 OOS survey also examined whether or not all WHO-recommended TB 356 medicines were included on national Essential Medicine Lists, which can help ease drug 357 importation. 17 Alternative access mechanisms may become increasingly important to avoid country-358 level shortages or stock-outs of TB drugs amid worrying global shifts in funding and support. Looking ahead based on these findings, we hope the pace of implementation of improvements in TB 376 care, including newer WHO recommendations that have come out since the survey, will increase 377 more than they have in the past. The factors affecting why countries may be slow to adopt new 378 policies and implement them for certain TB care recommendations is an area worthy of further 379 research and analysis. While the lack of research in critical areas itself needs to be addressed, 380 countries need to be bold and rapidly adopt available WHO guidance in these areas. The WHO itself 381 stated in its August 2018 update on MDR-TB treatment, "While understanding that it would not be 382 immediately possible to achieve the new standards of care in every individual MDR-TB patient, 383 strategic planning should start immediately to enable rapid transition to the upcoming new WHO 384
guidelines." 27 Not doing so will continue to unnecessarily leave thousands of people affected by TB 385 without access to new health tools that could save their lives. 386
For any hope to achieve global TB health targets set by the UN High-Level Meeting on TB Political 387 Declaration and UN Sustainable Development Goals, greater political will, funding, and resources are 388 needed to implement the best possible TB care strategies and tools. Also, research and development 389 into new, more effective and appropriate tests and treatments is urgently needed. If countries make 390 bold, impactful efforts to fall in step with the latest international TB policies, we may finally put 391 ourselves on track to see an end to the global TB crisis. 392 S1 Text. Supplementary methods 404
